98 related articles for article (PubMed ID: 10523834)
1. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.
Caruana G; Cambareri AC; Ashman LK
Oncogene; 1999 Sep; 18(40):5573-81. PubMed ID: 10523834
[TBL] [Abstract][Full Text] [Related]
2. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
[TBL] [Abstract][Full Text] [Related]
3. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
4. Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement.
Caruana G; Cambareri AC; Gonda TJ; Ashman LK
Oncogene; 1998 Jan; 16(2):179-90. PubMed ID: 9464535
[TBL] [Abstract][Full Text] [Related]
5. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
7. FGF-8 isoforms differ in NIH3T3 cell transforming potential.
MacArthur CA; Lawshé A; Shankar DB; Heikinheimo M; Shackleford GM
Cell Growth Differ; 1995 Jul; 6(7):817-25. PubMed ID: 7547503
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
9. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
10. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Ning ZQ; Li J; McGuinness M; Arceci RJ
Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
[TBL] [Abstract][Full Text] [Related]
11. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
[TBL] [Abstract][Full Text] [Related]
12. Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor.
Samayawardhena LA; Hu J; Stein PL; Craig AW
Cell Signal; 2006 Sep; 18(9):1447-54. PubMed ID: 16442778
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction via the stem cell factor receptor/c-Kit.
Rönnstrand L
Cell Mol Life Sci; 2004 Oct; 61(19-20):2535-48. PubMed ID: 15526160
[TBL] [Abstract][Full Text] [Related]
14. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
15. Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.
Roskoski R
Biochem Biophys Res Commun; 2005 Nov; 337(1):1-13. PubMed ID: 16129412
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC
J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110
[TBL] [Abstract][Full Text] [Related]
17. Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation.
Edling CE; Pedersen M; Carlsson L; Rönnstrand L; Palmer RH; Hallberg B
Br J Haematol; 2007 Jan; 136(2):260-8. PubMed ID: 17156394
[TBL] [Abstract][Full Text] [Related]
18. Role of stem cell factor and c-kit signaling in regulation of fetal intestinal epithelial cell adhesion to fibronectin.
Shimizu M; Minakuchi K; Tsuda A; Hiroi T; Tanaka N; Koga J; Kiyono H
Exp Cell Res; 2001 Jun; 266(2):311-22. PubMed ID: 11399059
[TBL] [Abstract][Full Text] [Related]
19. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
20. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma.
Plo I; Lautier D; Casteran N; Dubreuil P; Arock M; Laurent G
Oncogene; 2001 Oct; 20(46):6752-63. PubMed ID: 11709710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
